Integrity Alliance LLC. Has $4.41 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Integrity Alliance LLC significantly increased its stake in Thermo Fisher Scientific Inc. by 735.7%, now holding 8,867 shares worth approximately $4.41 million.
• Thermo Fisher Scientific reported a quarterly earnings per share of $5.36, exceeding estimates, alongside a revenue of $10.86 billion, showing a year-over-year increase of 2.9%.
• The company recently announced a quarterly dividend of $0.43 per share, providing an annual yield of 0.4%, with a low dividend payout ratio of 9.95%.

Integrity Alliance LLC. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 735.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,867 shares of the medical research company's stock after buying an additional 7,806 shares during the period. Integrity Alliance LLC.'s holdings in Thermo Fisher Scientific were worth $4,412,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth $25,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter worth $31,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific in the 1st quarter worth $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter worth $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.8%

Thermo Fisher Scientific stock opened at $483.80 on Wednesday. The stock has a market cap of $182.69 billion, a P/E ratio of 27.98, a P/E/G ratio of 2.60 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company's 50-day moving average price is $463.59 and its two-hundred day moving average price is $452.20.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research note on Friday, July 11th. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Barclays boosted their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Finally, William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating on the stock. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $589.38.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 in the last quarter. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.